Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
Finckh, Axel
Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis. [electronic resource] - Annals of internal medicine Nov 2009 - 612-21 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1539-3704
10.7326/0003-4819-151-9-200911030-00006 doi
Anti-Inflammatory Agents, Non-Steroidal--economics
Antirheumatic Agents--economics
Arthritis, Rheumatoid--diagnostic imaging
Cost-Benefit Analysis
Decision Support Techniques
Disease Progression
Glucocorticoids--economics
Health Care Costs
Humans
Immunologic Factors--economics
Methotrexate--economics
Quality-Adjusted Life Years
Radiography
Treatment Outcome
Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis. [electronic resource] - Annals of internal medicine Nov 2009 - 612-21 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1539-3704
10.7326/0003-4819-151-9-200911030-00006 doi
Anti-Inflammatory Agents, Non-Steroidal--economics
Antirheumatic Agents--economics
Arthritis, Rheumatoid--diagnostic imaging
Cost-Benefit Analysis
Decision Support Techniques
Disease Progression
Glucocorticoids--economics
Health Care Costs
Humans
Immunologic Factors--economics
Methotrexate--economics
Quality-Adjusted Life Years
Radiography
Treatment Outcome